With a portfolio of 850+ finished dosage products across 45 therapeutic areas and 12 specialities. Our patient-centric generics and proprietary formulations, backed by global approvals, are manufactured in accredited facilities in India, USA, and Ethiopia to ensure reliable access and improved treatment outcomes worldwide.
Cadila Pharma’s R&D is driven by a single mission: to turn scientific innovation into accessible, life-changing healthcare. With state-of-the-art facilities for formulation, we transform ideas from molecule to market, ensuring every therapy we create makes a meaningful difference in people’s lives.
Each product begins with a clear, data-driven target product profile (TPP), designed to meet the unique needs of patients and clients alike. Our approach is rooted in quality, leveraging Quality by Design (QbD), Modelling, and Design of Experiments (DoE) to ensure efficacy, safety, and compliance with the highest global standards.
Through every discovery, every formulation, and every breakthrough, Cadila Pharma’s R&D strives to redefine what’s possible in healthcare, making therapies not just innovative but accessible, reliable, and transformative.
sq. ft. area of R&D facility
diligent and committed scientists
From concept to complex formulations, our R&D infrastructure enables precision, speed, and scalability. Supported by a deeply specialised team, it fuels continuous innovation across high-value ANDAs and alternative dosage development.
Based in Ahmedabad, the facility has a range of state-of-the-art equipment for formulation development, working on different dosage forms such as tablets, capsules, powders, oral liquids, injectables, and ophthalmics.
It is also equipped with sophisticated instruments such as LC-MS, HPLC, GC, a Malvern Mastersizer 3000, and more.
Our R&D strategy is led by a world-class in-house development team and supplemented by creative product development partnerships with external stakeholders. The focus of our R&D strategies is to ensure the ongoing innovation of important, value-generating products across our portfolios.
We are committed to expanding our Affordable Medicines business by targeting complex and alternative dosage form Abbreviated New Drug Applications (ANDAs) with high-value, difficult-to-develop, first-to-file or first-to-market product opportunities.
The pipeline includes products across a broad range of therapeutic areas, including cardiovascular, central nervous system/pain, oncology, inflammation, anti-infective, dermatology, endocrinology, diabetes, rhinology, urology, and haematology, among others.
We have developed several technology platforms for the controlled delivery of challenging compounds, significantly improving efficacy, tolerability, and compliance. Our Speciality R&D teams are working to leverage these technologies to enhance our pipeline, improve patient outcomes, and deliver value.
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
